Oxazolidines as 5-HT2A-antagonists

US6462056B1 · kind B1 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Henning Bottcher · Darmstadt, DE
• Helmut Prucher · Heppenheim, DE
• Hartmut Greiner · Darmstadt, DE
• Gerd Bartoszyk · Weiterstadt, DE
• Christoph Seyfried · Seeheim-Jugenheim, DE

Key dates

• Filing date: Aug 25, 1999
• Grant date: Oct 8, 2002
• Expiry date: Aug 25, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel oxazolidine derivatives of the formula in which R1, R2 and R3 have the meanings stated in claim 1, their salts and processes for preparing the compounds according to the invention.The compounds of the formula I act as 5-HT2A antagonists with a 5-HT reuptake-inhibiting, antidepressant or anxiolytic effect and can be used to produce pharmaceuticals.